SecBot SecBot
SECBOTREPLAY Home › Report › SYRE

SYRE · Spyre Therapeutics reported Q1 2026 financial results with a net loss…

Spyre Therapeutics, Inc. · 8-K filed May 5, 2026 at 08:05 ET

At the news

MIXEDIMPACT 6/10

8-K filed May 5, 2026 at 08:05 ET

Spyre Therapeutics reported Q1 2026 financial results with a net loss of $69.0M ($0.74 per share), wider than the $44.8M loss in Q1 2025, driven by higher R&D and G&A expenses and a $30.4M non-cash charge from CVR fair value changes. The company highlighted positive Phase 2 data for SPY001 in ulcerative colitis, over-enrollment of the RA sub-study, and a pro forma cash position of $1.18B following a $463M public offering, providing runway into H2 2029. The wider loss and lack of revenue (pre-revenue biotech) make this a neutral-to-bearish financial report, but the strong pipeline progress and extended cash runway are positive offsets.

  • Net loss of $69.0M in Q1 2026 vs $44.8M in Q1 2025, driven by higher R&D ($60.4M vs $41.6M) and G&A ($15.2M vs $11.9M) expenses
  • Pro forma cash of $1.18B as of March 31, 2026, including $435.3M net proceeds from April 2026 public offering, providing runway into H2 2029
  • Positive topline Phase 2 data for SPY001 in ulcerative colitis: 40% clinical remission, 51% endoscopic improvement, statistically significant RHI reduction
  • RA sub-study of SKYWAY Phase 2 trial over-enrolled, topline readout accelerated to Q3 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access